Johnson & Johnson announced that the FDA has issued traditional approval for Sirturo (bedaquiline) as part of combination therapy in adult and pediatric patients (5 years and older… read more.
Scientists in Canada believe they may be closer to understanding a positive additional benefit associated with Bacillus Calmette Guérin (BCG), a century-old vaccine for tuberculosis. It turns out… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for the Company’s medicine… read more.
In the first global assessment of TB among incarcerated people, a new study found consistently high TB case rates and low case detection in prisons, suggesting the need… read more.
AI software can accurately detect TB from chest X-rays, a study being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark,… read more.
The findings, published in Proceedings of the National Academy of Sciences (PNAS) today, may mean TB can be cured with shorter treatments. TB typically takes months to treat with multiple… read more.
Tuberculosis can be tough to detect. Diagnosis usually requires coughing up a sputum sample from the lungs, which can be unpleasant, impractical, and even hazardous. But in a… read more.
Multiple does of the Bacillus Calmette-Guerin (BCG) vaccine appears to offer patients with type 1 diabetes strong protection against COVID-19, researchers reported on August 15, 2022 in Cell… read more.
Mycobacterium tuberculosis, the causative agent of tuberculosis, remains the leading cause of infectious disease worldwide, affecting approximately a quarter of the globe’s population. Treatment of infections is problematic… read more.
Briefly blocking a key molecule when administering the only approved vaccine for tuberculosis vastly improves long-term protection against the devastating disease in mice, researchers from Texas Biomedical Research… read more.
Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis. Mycobacterium tuberculosis (Mtb)… read more.
Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
